- Home
- ACOG vs ORMP Comparison
ACOG vs ORMP Comparison
Compare ACOG & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- ORMP
- Stock Information
- Founded
- ACOG 2000
- ORMP 2002
- Country
- ACOG Canada
- ORMP United States
- Employees
- ACOG N/A
- ORMP N/A
- Industry
- ACOG
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- ACOG
- ORMP Health Care
- Exchange
- ACOG Nasdaq
- ORMP Nasdaq
- Market Cap
- ACOG 80.3M
- ORMP N/A
- IPO Year
- ACOG N/A
- ORMP N/A
- Fundamental
- Price
- ACOG $10.69
- ORMP $2.20
- Analyst Decision
- ACOG Strong Buy
- ORMP Hold
- Analyst Count
- ACOG 1
- ORMP 1
- Target Price
- ACOG $20.00
- ORMP N/A
- AVG Volume (30 Days)
- ACOG 71.5K
- ORMP 77.2K
- Earning Date
- ACOG 08-14-2025
- ORMP 08-15-2025
- Dividend Yield
- ACOG N/A
- ORMP N/A
- EPS Growth
- ACOG N/A
- ORMP N/A
- EPS
- ACOG N/A
- ORMP N/A
- Revenue
- ACOG $2,928,654.00
- ORMP $2,000,000.00
- Revenue This Year
- ACOG N/A
- ORMP N/A
- Revenue Next Year
- ACOG N/A
- ORMP N/A
- P/E Ratio
- ACOG N/A
- ORMP N/A
- Revenue Growth
- ACOG N/A
- ORMP 196.74
- 52 Week Low
- ACOG $3.75
- ORMP $1.82
- 52 Week High
- ACOG $11.40
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- ACOG N/A
- ORMP 49.72
- Support Level
- ACOG N/A
- ORMP $2.10
- Resistance Level
- ACOG N/A
- ORMP $2.25
- Average True Range (ATR)
- ACOG 0.00
- ORMP 0.09
- MACD
- ACOG 0.00
- ORMP 0.00
- Stochastic Oscillator
- ACOG 0.00
- ORMP 63.16
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.